Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Director Buys $9,999,999.90 in Stock

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Director Aron R. English bought 10,101,010 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were acquired at an average cost of $0.99 per share, for a total transaction of $9,999,999.90. Following the transaction, the director now directly owns 15,467,300 shares in the company, valued at approximately $15,312,627. This trade represents a 188.23 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Anebulo Pharmaceuticals Stock Up 4.9 %

Shares of Anebulo Pharmaceuticals stock opened at $1.70 on Friday. Anebulo Pharmaceuticals, Inc. has a 52-week low of $0.80 and a 52-week high of $3.30. The firm’s 50 day moving average price is $1.57 and its 200-day moving average price is $1.93. The company has a market cap of $44.09 million, a P/E ratio of -5.67 and a beta of -1.09.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last announced its earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.08. As a group, equities research analysts forecast that Anebulo Pharmaceuticals, Inc. will post -0.52 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $8.00 target price on shares of Anebulo Pharmaceuticals in a research report on Tuesday, November 19th.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.